Spotlight
Clinical Role
Clinical
Supplement Spotlight
CME/CE
Subscribe
The Mechanism of Action of Inclisiran for LDL-C Management in ASCVD
Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discussed inclisiran’s mechanism of action and how it supports LDL-C management for patients with ASCVD.
Pharmacy Times interviewed Norman Lepor, MD, a Los Angeles-based cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), on the burden of atherosclerotic cardiovascular disease (ASCVD) and low-density lipoprotein cholesterol (LDL-C) management.
During the discussion, Lepor explained inclisiran’s mechanism of action and how it supports LDL-C management for patients with ASCVD.
Related Videos
Related Content
